US Patent 8,685,442: Levodopa Inhalation Capsule Claims, Patent Scope, Expiration, and Competitive Landscape

US Patent No. 8,685,442 protects a specific levodopa inhalation capsule configuration associated with low-density dry-powder levodopa products. The independent claim requires four central elements: an HPMC capsule shell containing titanium dioxide, a levodopa powder with at least 75% levodopa by weight, a working density of approximately 0.02 to 0.1 g/cm³, and superior powder emission compared with an HPMC capsule without titanium dioxide.[1]

The patent is directed to the capsule-and-powder combination, not levodopa inhalation therapy generally. A competing product that omits titanium dioxide, uses a shell material other than HPMC, or falls outside the claimed powder-density and levodopa-concentration ranges may avoid literal infringement of claim 1, subject to the doctrine of equivalents and the complete patent estate covering the product.

What does US Patent 8,685,442 cover?

US 8,685,442 covers a capsule filled with a low-density, high-levodopa dry powder for actuation in an inhalation device. The claim has both structural and performance limitations.

Claim element	Requirement in claim 1	Scope significance
Dosage form	Capsule for use in an inhalation device	Excludes ordinary oral capsules and non-capsule inhalers
Shell material	HPMC	Requires hydroxypropyl methylcellulose in the capsule shell
Shell additive	Titanium dioxide	A central distinguishing limitation
Active ingredient	Levodopa	The claim is directed to levodopa powder
Levodopa content	At least about 75% by weight	Applies to the dry powder composition
Powder density	About 0.02 to 0.1 g/cm³	Limits the powder to a low-density range
Functional performance	Emits more levodopa powder than an HPMC capsule without titanium dioxide	Adds a comparative powder-emission requirement
Inhalation use	Capsule is used in an inhalation device	Links the product to inhaled delivery

The claim does not expressly require sodium chloride, DPPC, a 00 capsule, a specific levodopa dose, or a particular fine-particle fraction. Those features appear in dependent claims and narrow the scope only when a dependent claim is asserted.

How do claims 1 through 14 differ?

Claim 1 is the broadest independent claim in the set. Claims 2 through 14 add formulation, capsule-size, dose, and aerosol-performance limitations.

Claim	Added limitation	Practical effect
1	HPMC/titanium-dioxide capsule; low-density powder; at least 75% levodopa; greater emission	Core capsule and powder combination
2	Working density of about 0.02 to 0.05 g/cm³	Narrows the density range to the lower half
3	Water content of about 2% to 8%	Adds powder moisture limitation
4	Water content of about 5% to 6%	Narrower moisture range
5	00-size capsule	Limits capsule dimensions
6	15 to 50 mg levodopa	Adds dose range
7	25 to 35 mg levodopa	Narrower dose range
8	Salt in the powder	Covers salt-containing formulations
9	Sodium chloride	Identifies the salt
10	Phospholipid	Adds a phospholipid excipient
11	DPPC	Identifies dipalmitoylphosphatidylcholine
12	DPPC and sodium chloride	Specifies the combination
13	Fine-particle fraction of about 50% to 70% of nominal dose	Adds aerosol-performance limitation
14	30 to 50 mg total dry powder	Limits total fill mass

Claim 12 is commercially important because it tracks the type of excipient combination used in high-load inhaled levodopa formulations. Claims 5, 6, 7, and 14 create a more product-specific cluster around a 00 capsule containing approximately 25 to 35 mg levodopa in a total fill of 30 to 50 mg.

What is the strongest limitation in US 8,685,442?

The titanium-dioxide requirement is the most distinctive structural limitation in claim 1. The claim does not merely require an HPMC capsule. It requires HPMC plus titanium dioxide and requires that the titanium-dioxide-containing capsule emit more levodopa powder than an HPMC capsule without titanium dioxide.

This structure gives the patent a narrower but more technically focused scope than a claim covering any HPMC capsule filled with levodopa.

The functional comparison is also significant. A product could contain HPMC and titanium dioxide but still present an infringement dispute if the accused product does not satisfy the claimed comparative-emission result. The likely evidence would include:

Capsule composition records.
Titanium-dioxide concentration.
Capsule moisture and mechanical properties.
Powder fill weight and density.
Inhaler actuation testing.
Emitted dose and emitted mass.
Comparative testing against an HPMC capsule without titanium dioxide.
Fine-particle fraction measurements.

The claim does not state a numerical minimum for the increased emission. The phrase "emits more powder" therefore creates a binary comparison rather than a specified percentage improvement. The comparison conditions, inhaler, actuation force, capsule puncture pattern, storage conditions, and analytical method could become central in litigation.

What are the infringement risks for an inhaled levodopa product?

A product may present a high literal-infringement risk if it has all of the following characteristics:

An HPMC capsule shell containing titanium dioxide.
A levodopa powder containing at least 75% levodopa by weight.
A working density from about 0.02 to 0.1 g/cm³.
A demonstrated increase in powder emission relative to a titanium-dioxide-free HPMC capsule.

The dependent-claim risk increases when the product also has a 00 capsule, 25 to 35 mg levodopa, 5% to 6% water, DPPC, sodium chloride, and 50% to 70% fine-particle fraction.

A product that meets claim 1 may infringe even if it does not meet claims 2 through 14. Conversely, failure to meet a dependent limitation does not avoid claim 1.

Potential design-around positions

Design-around approach	Claim 1 impact
Use a gelatin shell	Avoids the express HPMC limitation
Use HPMC without titanium dioxide	Avoids the titanium-dioxide limitation
Use another inorganic pigment or opacifier	May avoid literal titanium-dioxide coverage
Keep levodopa below 75% by weight	Avoids the composition threshold
Use powder density outside 0.02 to 0.1 g/cm³	Avoids the density range, subject to range interpretation
Use a non-capsule inhaler	Avoids the capsule limitation
Use a capsule that does not improve emission versus the comparator	Creates a dispute over the functional limitation
Change DPPC, sodium chloride, dose, or moisture	Avoids selected dependent claims, but not necessarily claim 1

A design-around based only on changing DPPC, sodium chloride, capsule size, or dose is weak against claim 1 because those features are not required by the independent claim.

When does US Patent 8,685,442 lose exclusivity?

The patent was granted on April 1, 2014.[1] Its published priority chain reaches September 1, 2009. On a standard US patent-term calculation, the 20-year term runs from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable regulatory extension.

The base term is therefore expected to reach approximately September 2029, before any patent-term adjustment or extension. The operative expiration date should be confirmed against the USPTO patent record and Orange Book listing because the final date can differ from the simple 20-year calculation.

Event	Date
Earliest reported priority date	September 1, 2009
US patent grant	April 1, 2014
Standard base-term endpoint	Approximately September 2029
Patent-term adjustment	Must be checked in the USPTO record
Patent-term extension	Must be checked separately from the patent term

The patent is not a biologic patent and does not create biosimilar exclusivity. It is relevant to generic or follow-on inhaled levodopa products submitted through the ANDA pathway or, depending on the product, another FDA pathway.

What is the FDA and Orange Book status of the patent?

The commercial product most closely associated with this technology is Inbrija, an inhaled levodopa product developed by Civitas Therapeutics and commercialized by Acorda Therapeutics. The FDA approved Inbrija on December 21, 2018, under NDA 209184 for intermittent treatment of "OFF" episodes in patients with Parkinson's disease treated with carbidopa/levodopa.[2]

Inbrija uses a capsule-based inhalation system and a dry powder containing levodopa and excipients. The FDA-approved product is administered with the Inbrija inhaler, rather than by conventional oral inhalation equipment.[2]

The relevant regulatory and patent issues are separate:

FDA approval establishes the approved product, indication, strength, and delivery device.
Orange Book listing identifies patents submitted by the NDA holder for the approved drug.
A patent's presence in the Orange Book does not by itself establish infringement.
An ANDA applicant may submit a Paragraph IV certification challenging an Orange Book-listed patent.
The patent holder may sue within the statutory period after receiving a Paragraph IV notice, triggering the Hatch-Waxman litigation framework.

Current Orange Book entries and any patent-use-code information should be reviewed for the specific NDA and listed patent family. Patent listing status can change through delisting, expiration, correction, or FDA administrative action.[3]

Are there Paragraph IV challenges to US 8,685,442?

A Paragraph IV challenge requires an ANDA applicant to certify that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Publicly identifying a challenge requires an ANDA filing, a notice letter, a district-court complaint, or an FDA first-applicant record.

The key litigation triggers are:

FDA receipt of an ANDA containing a Paragraph IV certification.
Notice to the NDA and patent holders.
A patent-infringement complaint filed within 45 days.
A potential 30-month stay of final approval under Hatch-Waxman.
Court resolution, settlement, or expiration of the stay.

The claim structure creates several possible Paragraph IV theories:

The generic capsule uses HPMC without titanium dioxide.
The product does not satisfy the comparative-emission limitation.
The powder has less than 75% levodopa.
The working density falls outside the claimed range.
The claims are invalid for anticipation or obviousness.
The functional language is indefinite or lacks adequate objective boundaries.
The specification does not enable the full breadth of the claimed density and emission ranges.

A generic applicant would likely challenge the patent through a product-specific certification rather than rely on a broad assertion that all inhaled levodopa products are outside the patent.

What validity issues affect the patent?

Anticipation

Anticipation requires a single prior-art reference to disclose every claim limitation arranged as claimed. A reference showing levodopa dry powder in an HPMC capsule may not anticipate claim 1 if it lacks titanium dioxide, the specified density, or the comparative-emission result.

The strongest anticipation reference would disclose:

HPMC capsule shells containing titanium dioxide.
Low-density levodopa powder.
At least 75% levodopa.
Use in an inhalation device.
Greater emission than an otherwise comparable titanium-dioxide-free HPMC capsule.

Obviousness

Obviousness may be stronger than anticipation if prior art separately teaches:

HPMC capsules for inhalation.
Titanium dioxide as a capsule opacifier or mechanical-property modifier.
High-load levodopa powders.
Low-density engineered particles.
DPPC and sodium chloride excipient systems.
Capsule emission improvements from shell composition.

The patent holder would likely argue that the claimed titanium-dioxide effect was unexpected and that the prior art did not provide a reason to combine the relevant capsule and powder features with a reasonable expectation of improved emission.

Indefiniteness

Potential indefiniteness issues center on:

"Working density."
"Emits more powder."
The comparator HPMC capsule.
Test conditions for actuation and emission.
Whether the comparison requires identical capsule size, moisture, fill weight, and inhaler conditions.
The analytical method used to quantify powder emission.

The specification, prosecution history, and industry testing practice would determine whether these terms have reasonably certain boundaries.

Written description and enablement

The patent must support the claimed density range, levodopa concentration, capsule composition, emission improvement, and dependent excipient combinations. A challenge could focus on whether the disclosure supports the full breadth of the ranges, particularly if the improved-emission result depends on unclaimed variables such as titanium-dioxide loading, capsule wall thickness, water content, storage conditions, or inhaler geometry.

What other patents protect Inbrija and inhaled levodopa?

US 8,685,442 is one component of the broader Inbrija patent estate. Commercial protection can be divided into several technical groups:

Patent group	Protected subject matter	Competitive relevance
Capsule patents	HPMC composition, titanium dioxide, capsule performance	Directly relevant to the claimed product configuration
Formulation patents	High-load levodopa powders, particle engineering, excipient systems	Can block a generic even if it designs around the capsule
Device patents	Inhaler architecture, piercing, dispersion, airflow, dose delivery	May create separate device infringement risk
Method-of-use patents	Intermittent treatment of Parkinson's disease OFF episodes	Relevant to labeling and induced-infringement theories
Manufacturing patents	Spray drying, particle formation, blending, filling, and moisture control	Can increase development and scale-up barriers
Regulatory exclusivity	NDA and FDA approval protections	Operates separately from patent rights

A freedom-to-operate review cannot stop at US 8,685,442. A follow-on product may avoid the capsule claim but still infringe formulation, inhaler-device, manufacturing, or method-of-use patents.

How strong is the patent estate for inhaled levodopa?

US 8,685,442 has moderate-to-strong product-specific value and weaker platform breadth.

Its strength comes from the combination of:

A defined capsule material.
A specific titanium-dioxide limitation.
A high levodopa loading threshold.
A low powder-density range.
A measurable powder-emission result.

Its weakness is the number of design variables available to a competitor. A competing developer can investigate a gelatin or alternative polymer capsule, omit titanium dioxide, modify powder density, use a different levodopa concentration, or develop a non-capsule delivery system.

The commercial barrier may remain substantial because a successful competitor must also match:

Fine-particle delivery.
Dose uniformity.
Device compatibility.
Moisture stability.
Manufacturing yield.
Patient usability.
FDA requirements for an inhaled drug-device combination.

Which companies are challenging the Inbrija patent estate?

Inbrija was developed by Civitas Therapeutics and acquired by Acorda Therapeutics in 2014. Merz acquired Acorda in 2020, including Inbrija and related assets.[4,5]

Publicly established ownership and commercialization history is:

Company	Role
Civitas Therapeutics	Original developer of the inhaled levodopa technology
Acorda Therapeutics	Acquired Civitas and commercialized Inbrija
Merz Therapeutics	Acquired Acorda and assumed the Inbrija business

No biosimilar competition applies because levodopa is a small-molecule active ingredient. Potential competition would arise through an ANDA generic, a 505(b)(2) product, or a therapeutically differentiated inhaled levodopa product.

The principal commercial risks are therefore generic entry, device substitution, and reformulated inhaled levodopa products rather than biosimilar entry.

What generic launch scenarios exist?

Launch after patent expiration

The clearest scenario is an ANDA approval after expiration of US 8,685,442 and any other blocking patents or regulatory stays. This path would require the generic to address the listed patents and demonstrate pharmaceutical equivalence, bioequivalence, device performance, manufacturing quality, and inhaled-product safety.

Paragraph IV launch

An ANDA applicant could challenge the patent before expiration. A successful invalidity or noninfringement decision could permit early approval. Settlement terms could also establish an agreed launch date, although settlement details depend on the parties and any antitrust review.

Non-infringing formulation

A generic could use a different capsule material or titanium-dioxide-free shell. This approach may avoid claim 1 but would require independent analysis of the formulation, device, method-of-use, and manufacturing patent families.

505(b)(2) product

A 505(b)(2) applicant could pursue a modified inhaled levodopa product with a different device, formulation, strength, or dosing regimen. This route would not automatically avoid patent infringement and may face listed-patent certifications or patent-use-code issues.

Key Takeaways

US 8,685,442 is a product claim covering a levodopa inhalation capsule, not inhaled levodopa generally.
Claim 1 requires HPMC, titanium dioxide, at least 75% levodopa, a working density of about 0.02 to 0.1 g/cm³, and superior emission versus a titanium-dioxide-free HPMC capsule.
DPPC, sodium chloride, 00 capsule size, specific dose ranges, water content, and fine-particle fraction are dependent-claim limitations.
The patent's standard base term runs to approximately September 2029, subject to patent-term adjustment and any extension.
The principal validity issues are anticipation, obviousness, indefiniteness of the functional emission language, and enablement of the claimed ranges.
A capsule-level design-around may avoid this patent while remaining exposed to formulation, inhaler-device, manufacturing, or method-of-use patents.
Inbrija was approved by the FDA in 2018 and was developed by Civitas, commercialized by Acorda, and later acquired by Merz.
Generic risk is more relevant than biosimilar risk because levodopa is a small molecule.
The commercial launch date for a generic depends on the full Orange Book patent estate, any Paragraph IV litigation, settlement terms, and regulatory approval.

FAQs About US Patent 8,685,442

Does US 8,685,442 cover all inhaled levodopa products?

No. It covers a specific capsule and dry-powder configuration. Inhaled levodopa delivered through a different capsule material, powder composition, density, or device may fall outside claim 1, although other patents may apply.

Is titanium dioxide required for infringement?

For literal infringement of claim 1, yes. The claim expressly requires a capsule shell comprising HPMC and titanium dioxide. The product must also satisfy the remaining claim limitations.

Does using DPPC automatically create infringement?

No. DPPC appears in claims 10, 11, and 12. DPPC alone does not establish infringement. The accused product must satisfy every limitation of the asserted claim.

Can a generic use a gelatin capsule to avoid the patent?

A gelatin capsule would not literally satisfy the HPMC limitation in claim 1. The generic would still need to evaluate the broader Inbrija patent estate, including formulation, device, manufacturing, and method-of-use patents.

Is US 8,685,442 a biologic or biosimilar patent?

No. It concerns an inhaled small-molecule levodopa product. The relevant follow-on pathway is generally an ANDA or potentially a 505(b)(2) application, not a biosimilar application.

References

United States Patent and Trademark Office. (2014). US Patent No. 8,685,442, capsule for use in an inhalation device. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2018). Inbrija (levodopa) inhalation powder: Prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
Acorda Therapeutics, Inc. (2014). Acorda Therapeutics to acquire Civitas Therapeutics. Company announcement.
Merz Pharma GmbH & Co. KGaA. (2020). Merz completes acquisition of Acorda Therapeutics. Company announcement.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes	8,685,442	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013342246	⤷ Start Trial
Australia	2013342247	⤷ Start Trial
Australia	2013342248	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,685,442

Which drugs does patent 8,685,442 protect, and when does it expire?

Summary for Patent: 8,685,442